Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer

Douglas H. Campbell, Maria E. Lund, Aline L. Nocon, Paul J. Cozzi, Mark Frydenberg, Paul De Souza, Belinda Schiller, Jennifer L. Beebe-Dimmer, Julie J. Ruterbusch, Bradley J. Walsh*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)
10 Downloads (Pure)

Abstract

While measurement of serum prostate specific antigen (PSA) is an important screening tool for prostate cancer, new biomarkers are necessary for better discrimination between presence and absence of disease. The MIL-38 monoclonal antibody is specific for the membrane glycoprotein glypican 1 (GPC-1) and binds to prostate cancer tissue. Urine is known to be a source of cellular material. Thus, we hypothesized that detection of GPC-1 in urine cellular material may identify individuals with prostate cancer. Urine samples from patients with prostate cancer, benign prostatic hyperplasia (BPH), or normal controls were collected and cell sediments prepared. GPC-1-positive cells were detected using a MIL-38 immunofluorescence assay (IFA) and samples were classed positive or negative for GPC-1 expressing cells. Assay sensitivity and specificity, stratified by PSA, was reported. A total of 125 patient samples were analyzed (N = 41 prostate cancer; N = 37 BPH; N = 47 normal controls). The use of MIL-38 to detect GPC-1 by IFA discriminated between prostate cancer and BPH urine specimens with a sensitivity and specificity of 71% and 76%, respectively. Assay specificity increased with increasing PSA, with the highest specificity (89%) for patients with PSA 4 ng/ml. At lower PSA (<2 ng/ml) specificity decreased, as evidenced by a greater number of false positives in this concentration range. The odds ratio (OR) and 95% confidence intervals (CIs) for GPC-1-positive cells in patients with prostate cancer, adjusted for PSA, was greatest at the lowest serum PSA (<2 ng/ml; OR = 13.4; 95% CI: 4.0–44.7) compared with no adjustment for PSA (OR = 6.4; 95% CI: 2.8–14.9). The use of MIL-38 for detection of GPC-1 may be a useful tool for detection of prostate cancer.

Original languageEnglish
Article numbere0196017
Number of pages12
JournalPLoS ONE
Volume13
Issue number4
DOIs
Publication statusPublished - 19 Apr 2018
Externally publishedYes

Bibliographical note

Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Fingerprint

Dive into the research topics of 'Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer'. Together they form a unique fingerprint.

Cite this